Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
Active, not recruiting · NCT05270525 · Registry updated 2026-09-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Effect of Ensifentrine on Sputum Markers of Inflammation in COPD | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-09-30 | NCT05270525 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Alabama at Birmingham | 467 |
| Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 2 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | United States | 26 |
| University of Michigan | Ann Arbor | United States | 538 |
| University of Pittsburgh Medical Center | Pittsburgh | United States | 127 |